Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 by Kuang, Dong-Ming et al.
ARTICLE
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 6  1327-1337
www.jem.org/cgi/doi/10.1084/jem.20082173
1327
Tumor progression is now recognized as the 
product of evolving cross talk between differ-
ent cell types within the tumor and its stroma 
(1, 2). Although normal stroma is nonpermis-
sive for neoplastic progression, cancer cells can 
modulate adjacent stroma to generate a sup-
portive microenvironment (1–3). This includes 
the ability to alter the ratios of effector to regu-
latory  T  cells  and  to  affect  the  functions  of 
APCs and the expression of cosignaling mole-
cules, which in turn creates an immunosuppres-
sive  network  to  promote  tumor  progression 
and immune evasion (3, 4). There is also emerg-
ing  evidence  that  the  proinflammatory  re-
sponse at the tumor stroma can be rerouted in 
a tumor-promoting direction (5). These obser-
vations suggest that different tumor microenvi-
ronments can create either immune suppression 
or activation at distinct sites to promote tu-
mor progression.
Macrophages (M) constitute a major com-
ponent of the leukocyte infiltrate in tumor 
stroma. These cells are derived almost entirely 
from circulating monocytes, and in response to 
environmental signals, they acquire special phe-
notypic characteristics that are associated with 
diverse functions (6–8). We have recently found 
that tumor environments can alter the normal 
development of M that is intended to trigger 
transient early activation of monocytes in the 
peritumoral region (7). Furthermore, in a study 
of patients with hepatocellular carcinoma (HCC) 
(5), it was noted that an increased number of 
activated monocytes/M (HLA-DRhighCD68+ 
cells) in the liver was associated with progression 
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Macrophages (M) are prominent components of solid tumors and exhibit distinct pheno-
types in different microenvironments. We have recently found that tumors can alter the 
normal developmental process of M to trigger transient activation of monocytes in 
peritumoral stroma. We showed that a fraction of monocytes/M in peritumoral stroma, 
but not in cancer nests, expresses surface PD-L1 (also termed B7-H1) molecules in tumors 
from patients with hepatocellular carcinoma (HCC). Monocytes activated by tumors 
strongly express PD-L1 proteins with kinetics similar to their activation status, and sig-
nificant correlations were found between the levels of PD-L1+ and HLA-DRhigh on tumor-
infiltrating monocytes. Autocrine tumor necrosis factor  and interleukin 10 released 
from activated monocytes stimulated monocyte expression of PD-L1. The PD-L1+ mono-
cytes effectively suppressed tumor-specific T cell immunity and contributed to the growth 
of human tumors in vivo; the effect could be reversed by blocking PD-L1 on those mono-
cytes. Moreover, we found that PD-L1 expression on tumor-infiltrating monocytes in-
creased with disease progression, and the intensity of the protein was associated with high 
mortality and reduced survival in the HCC patients. Thus, expression of PD-L1 on activated 
monocytes/M may represent a novel mechanism that links the proinflammatory response 
to immune tolerance in the tumor milieu.
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after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
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significantly larger amounts of PD-L1 (both P < 0.0001; Fig. 1, 
A–C). Moreover, we found that the ratios of PD-L1+CD14high 
cells  in  both  nontumor  and  tumor-derived  monocytes 
were higher in advanced stage HCC patients (stages III 
and IV; n = 13) than those in early stages (stages I and II; n = 
15; P < 0.05 for nontumor and P < 0.001 for tumor tissues; 
Fig. 1, A and B).
We subsequently examined the distribution of PD-L1+ 
cells in HCC samples. Using confocal microscopy, we con-
firmed that PD-L1 protein was expressed mainly on CD68+ 
monocytes/M (n = 10) and was only weakly expressed 
on other stromal and hepatoma cells (Fig. 1 D). Interest-
ingly, only CD68+ cells in the peritumoral stroma showed 
marked expression of PD-L1, whereas most CD68+ cells in 
the cancer nests were weakly expressed or negative for PD-L1 
(Fig. 1 D). Collectively, these data indicate that PD-L1 is se-
lectively expressed on monocytes/M in peritumoral stroma 
at levels that increase with progressive stages in HCC patients.
Tumor environmental factors induce early transient 
expression of PD-L1 on monocytes
We have recently shown that tumor microenvironments 
may co-opt the normal development of M to dynamically 
educate the recruiting monocytes in different niches of a tu-
mor (7). To investigate whether such mechanisms are also 
responsible for selective expression of PD-L1 on monocytes/
M in peritumoral stroma, we incubated normal blood 
monocytes with supernatants from cultures of hepatoma or 
normal liver cell lines. Exposure to 15% tumor culture su-
pernatants (TSNs) from hepatoma (SK-Hep-1 and HepG2) 
cells induced rapid expression of PD-L1 on monocytes, 
reaching a maximum within 36 h and then gradually declin-
ing (Fig. 2 A). On day 7, TSN-exposed M displayed signifi-
cantly reduced expression of PD-L1. In contrast, supernatant 
from normal liver cells (LO2) had only a marginal effect on 
PD-L1 expression by monocytes/M, even when used at a 
high concentration (30%).
APCs are more susceptible to express PD-L1 when they 
are activated (4, 15); hence, we examined the activation sta-
tus of TSN-exposed monocytes at their early or later differ-
entiation stage. The results showed that the expression of 
HLA-DR, CD80, and CD86 was significantly up-regulated 
on monocytes after exposure to TSNs from hepatoma cells 
for 24 h, but was reduced on day 7 when the cells developed 
into M (Fig. 2 B). Similar patterns of cytokine productions 
were obtained in TSN-exposed monocytes, including the 
accumulations of TNF-, IL-10, IL-6, IL-12, and IL-1 in 
the culture media at their early differentiation stage and a 
subsequent decline on day 7 (Fig. 2 C). Furthermore, com-
parison of the kinetics of PD-L1 expression and cytokine 
production in TSN-exposed monocytes revealed that cyto-
kine profiles preceded PD-L1 expression (Fig. 2 A) (7). These 
findings suggest that TSN-induced activation of monocytes 
led to expression of PD-L1. The TSNs we used did not con-
tain any measurable levels of TNF-, IL-10, IL-1, or IL-12, 
except for a low concentration of IL-6 (227 ± 53 pg/ml).
of the disease. Thus, immune functional data of activated 
monocytes/M in cancer environments are essential for un-
derstanding their roles and potential mechanisms in tumor 
immunopathogenesis.
PD-L1 (also termed B7-H1 and CD274) is a member of 
the B7 family of cosignaling molecules, and it possesses the 
dual functions of co-stimulation of naive T cells via an as 
yet unidentified receptor and coinhibition of activated ef-
fector T cells through PD-1 receptor (4, 9, 10). Expression 
of PD-L1 (B7-H1) is often induced or maintained by many 
inflammatory cytokines (4, 11), of which IFN- is the most 
potent. In addition to being expressed on activated immune 
cells, most human cancers also express high levels of PD-L1 
(B7-H1) protein, which correlates with poor prognosis in 
some cases (4, 11–13). In contrast, low or rare PD-L1 (B7-H1) 
expression is observed in most mouse and human tumor   
cell lines, possibly because of the lack of a complete cancer 
microenvironment in cell lines in vitro (4, 12). At present, 
little is known about the expression and function of PD-L1 
(B7-H1) on APCs in the inflammatory activated stroma of 
human tumors in situ.
HCC is the fifth most common cancer worldwide, with 
an extremely poor prognosis (14). By using HCC as a model 
system, the present study showed that PD-L1+ monocytes 
were accumulated in the peritumoral stroma area of cancers 
and increased with tumor progression. The pattern of PD-L1 
(B7-H1) expression coincided with the transient activation of 
monocytes/M during their initial exposure to the tumor 
environment. These activated PD-L1+ monocytes suppressed 
tumor-specific T cell immunity, and their high infiltration 
was associated with poor survival of the HCC patients. More-
over, we found that blocking PD-L1 (B7-H1) effectively at-
tenuated this monocyte-mediated T cell anergy and restored 
their antitumor activity in vivo. Therefore, PD-L1 (B7-H1) 
expression on activated monocytes may represent a novel 
mechanism by which the proinflammatory response is linked 
to immune tolerance in the tumor milieu.
RESULTS
PD-L1+ monocytes are highly enriched in the peritumoral 
stroma of HCC patients
To evaluate the potential role of PD-L1 in tumor immuno-
pathology, we examined surface expression of this protein on 
circulating leukocytes from HCC patients and healthy do-
nors, and on infiltrating leukocytes freshly isolated from tu-
mor and nontumor liver tissues of patients with various stages 
of HCC (n = 28 in each group). In all of the samples ana-
lyzed, 92 ± 7% of the PD-L1+ leukocytes were CD14high 
cells that were considered as monocytes. PD-L1 was weakly 
expressed  on  a  fraction  of  circulating  monocytes  in  both 
healthy donors and patients. Although the percentage of PD-
L1+ cells was increased in nontumor-infiltrating monocytes, 
their intensity of PD-L1 expression was low. Compared with 
nontumor-infiltrating monocytes, the monocytes isolated from 
the corresponding tumor tissues comprised a significantly 
greater proportion of PD-L1+CD14high cells and expressed JEM VOL. 206, June 8, 2009 
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manner. Although rhTNF- alone, at concentrations up to 
10 ng/ml, only had a marginal effect, it did synergistically in-
crease the IL-10–mediated PD-L1 expression on monocytes 
(Fig. 2 E). These findings imply that IL-10 is involved in   
PD-L1 expression on human monocytes, and that effect can 
be potentiated by TNF-.
We have recently observed that hyaluronan fragments con-
stitute a common factor produced by several types of human   
tumors, including hepatoma, to stimulate the production of 
TNF- and IL-10 (7, 16). Therefore, we examined whether 
hyaluronan fragments are involved in inducing expression of 
PD-L1 on monocytes. The results showed that the up-regula-
tion of PD-L1 protein on TSN-exposed monocytes was 
significantly impaired both by adding a hyaluronan-specific 
blocking peptide (Pep-1) (16–18) and by reducing hyaluronan 
levels in TSNs via silencing of hyaluronan synthase 2 in tumor 
cells (Fig. 2 D), both of which have been shown to attenuate 
the release of TNF- and IL-10 by these monocytes (7).
Autocrine cytokines from activated monocytes induce 
expression of PD-L1
Cytokines derived from myeloid cells have previously been 
found to induce expression of PD-L1 in human tumor DCs 
(11). To ascertain whether autocrine cytokines from acti-
vated monocytes contribute to the expression of PD-L1, we 
used specific neutralizing antibodies to abolish the effects of 
TNF-, IL-10, or IL-6. As expected, blocking IL-10 effec-
tively inhibited the up-regulation of PD-L1 protein (Fig. 2 D). 
Interestingly, monocyte PD-L1 expression was also partially 
attenuated by the anti–TNF- antibody, whereas it was not 
affected by treatment with a concentration of anti–IL-6 anti-
body that effectively neutralized IL-6 in the culture system 
(Fig. 2 D and Table S1). To gain further support for roles of 
TNF- and IL-10 in induction of PD-L1 on monocytes, we 
tested recombinant human (rh) cytokines in the culture sys-
tem. As shown in Fig. 2 E, rhIL-10 induced significant 
expression of PD-L1 on monocytes in a dose-dependent 
Figure 1.  Monocytes isolated from human HCC tumor tissue expressed PD-L1. (A–C) FACS analysis of PD-L1 expression on fresh monocytes iso-
lated from peripheral blood and tissues. The percentage of PD-L1+CD14high monocytes (A and B) and the mean fluorescence intensity (MFI) of PD-
L1+CD14high cells (C) are shown. The numbers of samples collected from patients and donors in A–C were as follows: blood from 28 healthy individuals, 
and 21 stage I and II and 7 stage III and IV HCC patients; and paired nontumor and tumor tissue from 15 stage I and II and 13 stage III and IV HCC pa-
tients. The data shown in A are representative dot plots of at least seven individuals from more than five independent experiments; B and C show the 
statistical analysis of these samples. The continuous and dashed horizontal bars in B represent median values. Results are expressed as means ± SEM.  
(D) Analysis of PD-L1 distribution in HCC samples by confocal microscopy. The micrographs at higher magnification show the stained peritumoral stroma 
region (1) and a cancer nest (2). Significant difference compared with healthy blood is indicated (***, P < 0.0001). 1 out of 10 representative micrographs 
is shown in D. Bar, 50 µm.1330 MONOCYTE ACTIVATION AND IMMUNE EVASION | Kuang et al.
Of note, most infiltrating CD8+ T cells were also located in 
the same area.
High infiltration of peritumoral PD-L1+ monocytes/M is 
correlated with disease stage and poor survival of patients
Based on our observation that in tissues from advanced stage 
HCC patients high levels of PD-L1 protein were expressed by 
CD68+ cells in peritumoral stroma, but not by those in intra-
tumoral or nontumoral areas, we predicted that the presence 
of peritumoral CD68+ cells would have an adverse effect on 
survival. To test this assumption, 262 HCC patients received 
curative resection with follow-up data and were divided into 
two groups according to the median value of peritumoral 
stroma CD68 density (low, ≤118 cells [n = 134]; high, >119 
cells [n = 128]). There was a positive association between the 
densities of CD68+ and PD-L1+ cells in peritumoral stroma 
(n = 35; linear regression, r = 0.783; P < 0.01; Fig. 4 A), but 
striking negative associations between the CD68+ cell density 
in that area and overall survival (OS) and disease-free survival 
(DFS), respectively (n = 262; P < 0.01 for both OS and DFS; 
Fig. 4 B). In contrast, CD68+ cells in the nontumor area had 
no impact on the prognosis of either OS or DFS (unpublished 
data). Peritumoral stroma CD68+ cell density was also asso-
ciated with tumor size (P = 0.032), tumor multiplicity   
(P = 0.003), and tumor node metastasis stage (P = 0.002; 
Table S2). Multivariate analysis revealed that the number of 
PD-L1 expression and activation of monocytes/M are 
correlated in peritumoral stroma in HCC patients
The results described above suggested that monocytes are 
activated by tumor environments to express PD-L1 protein 
during the early migration/differentiation stage. To test this, 
we examined the coexpression of PD-L1 and HLA-DR on 
monocytes freshly isolated from peripheral blood, tumor, or 
nontumor liver tissues from HCC patients (n = 28 for each 
group). Consistent with the results for PD-L1 expression, 
we observed a significantly increased percentage of CD14high 
cells with high HLA-DR intensity in the tumor tissues (63.3 ± 
3.7%; P < 0.001 for all; Fig. 3, A–C), and a higher ratio of 
HLA-DRhighCD14high cells in monocytes was found in tu-
mor masses from advanced stage HCC patients (stages III 
and IV [n = 13] vs. stages I and II [n = 15]; P < 0.01; Fig. 3 B). 
Approximately  90%  of  HLA-DRhighCD14high  cells  from   
tumors also expressed substantial amounts of PD-L1 (n = 28). 
Moreover,  significant  correlations  were  found  between   
the levels of PD-L1+ and HLA-DRhigh monocytes in all of 
the samples analyzed (n = 112; linear regression, r = 0.934; 
P < 0.0001; Fig. 3 D). The coexistence of HLA-DR and 
PD-L1 on monocytes/M was further confirmed by exam-
ining expression of these proteins in serial sections of HCC 
tumor samples. As shown in Fig. 3 E, most of the HLA-
DRhighCD68 cells were accumulated in the peritumoral 
stroma area, and they were also positive for PD-L1 (n = 15). 
Figure 2.  Tumor environments regulated PD-L1 expression on monocytes/M. (A) Monocytes were left untreated or cultured with the indicated 
supernatants for different times. (B and C) Monocytes were left untreated or cultured with supernatant from SK-Hep-1 cells (TSN) for the indicated 
times. (D) Monocytes were left untreated or pretreated for 1 h with the indicated blocking antibodies, Pep-1, or control peptide (Cpep), and were then 
incubated for 24 h with SK-Hep-1 TSN. In parallel, some untreated monocytes were incubated for 24 h with TSNs from mock or SiHAS2 cells. (E) Mono-
cytes were incubated for 24 h with rhIL-10 or rhTNF- at the indicated concentrations (ng/ml). The MFI of PD-L1 and expression of surface markers 
were determined by FACS, and the production of cytokines was assessed by ELISA. The histograms in B are representative of five separate experiments. 
Values given in A, C, D, and E represent the means ± SE of four separate experiments. *, P < 0.05; and **, P < 0.01 indicate a significant difference from 
untreated TSN-exposed monocytes (D) or untreated monocytes (E).JEM VOL. 206, June 8, 2009 
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cantly larger portion of the tumor-infiltrating cytotoxic cells 
expressed the PD-L1 receptor PD-1 (61 ± 11%; n = 7; P < 
0.001 compared with nontumor-infiltrating T cells; Fig. 5, 
B and C), which suggests that tumor monocytes may regu-
late T cell function via PD-L1 signals. To address that possi-
bility, we purified tumor monocytes (>50% of them were 
PD-L1+) and autologous tumor-infiltrating T cells from HCC 
tissues,  and  then  performed  ELISPOT  assays.  The  result 
showed that tumor T cells co-cultured with tumor mono-
cytes exhibited an impaired production of IFN-. Consis-
tent with our hypothesis, blockade of PD-L1 by preincubation 
of tumor monocytes with the mAb MIH1 (19, 20) could 
markedly enhance the ability of tumor T cells to produce 
IFN- (Fig. 5 D).
To further elucidate the effect of PD-L1+ monocytes on 
T cell immunity, we generated one control T cell line stimulated 
CD68+ cells in peritumoral stroma was an independent prog-
nostic factor of OS (Table I). These results suggest that an 
increase in numbers of peritumoral stroma CD68+ cells is cor-
related with progression of HCC and, therefore, might serve 
as an independent predictor of poor survival.
Monocyte-associated PD-L1 suppresses tumor-specific  
T cell immunity
The colocalization of PD-L1+CD68+ cells and CD8+ T cells 
in the peritumoral stroma of HCC tissues (Fig. 3 E) suggests 
that these monocytes/M promote tumor progression by 
impairing T cell immunity. Therefore, our next objective 
was to determine the role of PD-L1+ tumor monocytes in   
T cell suppression. Fig. 5 A shows that most of the CD8+  
T cells (78 ± 15%; n = 15) in peritumoral stroma were in 
close contact with PD-L1+ cells. Interestingly, a signifi-
Figure 3.  Expression pattern of PD-L1 was correlated with the activation pattern of monocytes/M in peritumoral stroma. (A–C) FACS analy-
sis of PD-L1 and HLA-DR expression in fresh monocytes isolated from peripheral blood and tissues. Representative data on PD-L1+HLA-DRhigh monocytes 
(A), percentages of HLA-DRhighCD14high monocytes (B), and the MFI of HLA-DR in HLA-DRhighCD14high monocytes (C) are shown. The samples collected and 
the numbers of donors in A–C were the same as in Fig. 1. The data shown in A are representative dot plots of at least seven individuals from more than 
five independent experiments; B and C show the statistics analysis of these samples. The continuous and dashed horizontal bars in B represent median 
values. Results are expressed as means ± SEM. (D) Positive correlations between the levels of PD-L1+ and HLA-DRhigh monocytes. The samples used in D 
were blood from healthy individuals, HCC patients, and paired nontumor and tumor tissues from HCC patients (n = 28 for each). (E) Adjacent sections of 
paraffin-embedded hepatoma samples stained with the indicated markers. The micrographs at higher magnification show the peritumoral stroma region (1) 
and a cancer nest (2). Significant difference compared with healthy blood is indicated (***, P < 0.0001). 1 out of 15 representative micrographs is  
shown in E. Bars, 150 µm.1332 MONOCYTE ACTIVATION AND IMMUNE EVASION | Kuang et al.
cifically inhibit the proliferation and exert their cytotoxicity 
against corresponding tumor cells, whereas the control T cell 
line hardly had any effect (Fig. S1, A and B). However, ex-
posure to TSN-treated PD-L1+ monocytes for 24 h induced 
dysfunctional T cells that had a low cytotoxicity as well as 
impaired capacities for proliferation, expression of the activa-
tion marker CD25, and production of IL-2 and IFN- (Fig. 6 
and Fig. S1 C). Consistent with our hypothesis, blockade   
of PD-L1 significantly attenuated such T cell suppression 
mediated by TSN-treated monocytes (Fig. 6 and Fig. S1 C). 
Collectively, these findings show that PD-L1 contributes to 
tumor monocyte–mediated suppression in vitro.
Blockade of monocyte-associated PD-L1 improves  
tumor-specific T cell immunity
To test the effect of monocyte PD-L1 on tumor-specific T 
cell  immunity  in  vivo,  we  treated  TSN-exposed  PD-L1+ 
monocytes with PD-L1 blocking or control antibody and then 
injected them together with autologous tumor-specific T cells 
into our established human nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice bearing HepG2- 
derived hepatoma. As expected, mice without T cell transfu-
sions, mice treated with tumor-specific T cells plus PD-L1+ 
monocytes or control antibody–treated PD-L1+ monocytes, 
showed progressive tumor growth. Supporting our hypothesis 
that tumor monocyte PD-L1 signals are immunopathological 
in vivo, mice treated with tumor-specific T cells plus PD-L1 
blocking antibody–treated monocytes showed reduced tumor 
volumes at each measurement time point from day 8 (n = 4 
mice per group; *, P < 0.05 compared with control antibody; 
Fig. 7). These data indicate that tumor monocytes defeat   
tumor-specific T cell immunity in vivo via PD-L1 signals and 
thereby contribute to tumor growth.
with  anti-CD3/CD28,  and  two  types  of  tumor-reactive   
T cell lines with HepG2- and U937-loaded APCs, respectively 
(Fig. S1, A and B). Both tumor-reactive T cell lines can spe-
Figure 4.  Accumulation of PD-L1+CD68+ cells in peritumoral 
stroma predicted poor survival in HCC patients. (A) Adjacent sections 
of paraffin-embedded hepatoma samples stained with an anti-CD68 or 
an anti–PD-L1 antibody. Different levels of M infiltration can be seen 
along the peritumoral region: I, none or slight; II, moderate; and III, 
strong. The dashed lines represent the edges of tumor, stroma, or normal 
tissues. Bars, 50 µm. (B) OS and DFS in 262 HCC patients in relation to 
CD68 density in peritumoral stroma. The patients were divided into two 
groups according to the median value of CD68+ M density in peritu-
moral stroma: red lines, low density (n = 134); blue lines, high density  
(n = 128). Cumulative OS and DFS time were calculated by the Kaplan-
Meier method and analyzed by the log-rank test.
Table I.  Univariate and multivariate analyses of factors associated with survival and recurrence
OS DFS
Univariate Multivariate Univariate Multivariate
Variables p-value HR 95% CI p-value p-value HR 95% CI p-value
Age, years (>48 vs. ≤48) 0.344 NA 0.643 NA
Gender (female vs. male) 0.461 NA 0.215 NA
HbsAg (positive vs. negative) 0.086 NA 0.127 NA
Cirrhosis (present vs. absent) 0.211 NA 0.09 NA
ALT, U/L (>42 vs. ≤42) 0.38 NA 0.883 NA
AFP, ng/ml (>25 vs. ≤25) 0.005 1.68 1.07–2.62 0.023 0.221 NA
Tumor size, cm (>5 vs. ≤5) 0.004 1.66 1.1–2.51 0.016 0.024 1.44 1–2.07 0.052
Tumor multiplicity (multiple vs. solitary) <0.001 1.32 0.61–2.84 0.485 0.017 1.11 0.55–2.23 0.773
Vascular invasion (present vs. absent) 0.002 2.1 1.19–3.74 0.011 0.006 1.88 1.1–3.23 0.022
Intrahepatic metastasis (yes vs. no) <0.001 2.18 1.06–4.5 0.035 0.007 1.58 0.79–3.16 0.195
TNM stage (III+IV vs. I+II) 0.014 0.68 0.37–1.26 0.219 0.034 0.96 0.56–1.63 0.869
Tumor differentiation (III+IV vs. I+II) 0.1 NA 0.308 NA
Fibrous capsule (present vs. absent) 0.263 NA 0.742 NA
Peritumoral stroma M (high vs. low) <0.001 1.67 1.15–2.42 0.007 0.003 1.33 0.94–1.88 0.113
Cox proportional hazards regression model. Variables used in multivariate analysis were adopted by univariate analysis. The underlined terms represent statistical significance. 
AFP, -fetoprotein; ALT, alanine aminotransferase; CI, confidence interval; HbsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; TNM, tumor node metastasis.JEM VOL. 206, June 8, 2009 
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levels of proinflammatory cytokines, including IL-1, IL-12, 
and TNF-. However, these activated APCs were unable to 
stimulate effective antitumor T cell responses, and instead 
they suppressed the T cell immunity both in vitro and in 
vivo, which suggests that such monocytes can actually benefit 
tumor progression. This notion is supported by our finding 
that the density of monocytes/M in peritumoral stroma was 
correlated with advanced disease stages and poor survival in 
HCC patients. Consistent with our results, other investiga-
tors have recently reported that the increased CD68+HLA-
DR+ cells in peritumoral liver tissues are positively associated 
with metastatic potential in HCC (5).
M are versatile, plastic cells that can respond to environ-
mental signals through diverse functional programs (6, 29). 
We have recently shown that tumors dynamically regulate 
recruiting monocytes at distinct sites, which leads to transient 
activation of monocytes in peritumoral stroma and subse-
quent formation of suppressive M in cancer nests (7). The 
present study provided evidence that a fraction of these acti-
vated monocytes express PD-L1, and that those cells signifi-
cantly inhibit tumor-specific T cell proliferation, cytokine 
production, and cytotoxic potential in vitro. We also found 
that PD-L1+ monocytes inhibited tumor-specific immunity 
in vivo and fostered tumor growth in NOD/SCID mice 
bearing human tumors. Several of our observations support 
DISCUSSION
Much research has been focused on tumor-mediated immuno-
suppression over the past decade (4, 21). However, in spite of 
the generalized immunosuppressive status in cancer patients, 
many malignancies arise at sites of chronic inflammation, and 
inflammatory mediators are often produced in tumors (22–24). 
The present study demonstrates that the activated monocytes 
in a tumor microenvironment express PD-L1 (B7-H1) mole-
cules to suppress tumor-specific T cell function, which may 
represent a novel link between proinflammatory response and 
immune tolerance in the tumor milieu.
Human tumor tissues can be anatomically classified into 
areas of intratumoral and peritumoral stroma, each with dis-
tinct compositions and functional properties (5, 7, 24, 25). 
Intratumoral environments usually contain abundant immuno-
suppressive molecules and cells to inhibit the T cell re-
sponses and create conditions that are conducive to tumor 
growth (21, 26–28). In contrast, the stromal areas in most   
tumors contain a significant amount of leukocyte infiltrate, 
which was long assumed to represent the host response to the 
malignancy. In the current study, we observed that mono-
cytes in the peritumoral stroma had an activated phenotype 
with increased expression of HLA-DR, CD80, and CD86 
(Fig. 3 and not depicted). Data from an in vitro study showed 
that such tumor-activated monocytes produced significant 
Figure 5.  Tumor-derived monocytes induced T cell suppression via PD-L1. (A) Physical contact between PD-L1+ cells (red) and CD8+ cytotoxic  
T cells (green) in HCC peritumoral stroma. One out of five representative micrographs is shown in A. Bar, 20 µm. (B and C) Increased expression of PD-1 
protein on the surface of tumor-infiltrating T cells from HCC patients. The samples used in B and C were fresh blood from healthy individuals and HCC 
patients, and paired nontumor and tumor tissues from HCC patients (n = 7 for each). The data shown in B are representative dot plots of seven patients 
from six independent experiments. The horizontal bars in C represent median values. (D) HCC-derived monocytes induced anergy of tumor T cells with 
reduced IFN- production. Purified tumor T cells were left untreated (1), or were incubated for 20 h with autologous tumor monocytes supplemented 
with 25 µg/ml of autologous tumor mass lysate in the absence (2) or presence of 5 µg/ml of control (3) or anti–PD-L1 antibody (4). Thereafter, production 
of IFN- was determined by ELISPOT. Three out of six representative patient samples are shown in D.1334 MONOCYTE ACTIVATION AND IMMUNE EVASION | Kuang et al.
stroma. Fourth, expression of PD-L1 on tumor-infiltrating 
monocytes was increased with HCC progression, and greater 
intensity of such protein was associated with high mortality 
and reduced survival in the patients. Therefore, expression of 
PD-L1 on activated monocytes may represent a novel mech-
anism that represses antitumor T cell immunity.
PD-L1 is a cell-surface glycoprotein belonging to the B7 
family of cosignaling molecules with a profound regulatory 
effect on T cell responses (30–32). Studies in mouse models 
have revealed that expression of PD-L1 helped dormant 
tumor cells to evade cytotoxic T cell responses (33, 34).   
Although expression of PD-L1 protein is often found on acti-
vated cells and various human carcinomas, the regulatory 
mechanisms of human PD-L1 remain to be defined. We found 
that autocrine TNF- and IL-10, but not IFN-, released 
the notion that tumor monocyte PD-L1 signals contribute to 
immunopathology. First, tumor-activated monocytes in our 
experiments strongly expressed PD-L1 molecules with ki-
netics similar to their activation status, and significant cor-
relations were found between the levels of PD-L1+ and 
HLA-DRhigh on tumor-infiltrating monocytes. Second, these 
PD-L1–expressing monocytes effectively suppressed the tu-
mor-specific T cell immunity, and that effect was attenuated 
by blocking PD-L1 on these monocytes. Third, expression of 
the PD-L1 receptor PD-1 was significantly increased on tu-
mor-infiltrating T cells, and many of those cells were in close 
contact with activated PD-L1+ monocytes in peritumoral 
Figure 6.  TSN-exposed monocytes induced T cell suppression via 
PD-L1. Autologous monocytes (MO) or TSN-treated monocytes (PD-L1+ 
MO) were pretreated with 10 µg/ml mitomycin C for 30 min and were 
then washed and incubated with tumor-specific T cells (1:10) in the pres-
ence or absence of 5 µg/ml anti–PD-L1 or control antibody, as described 
in Materials and methods. The expression of CD25 on (A) T cells, (B) perfo-
rin in CD8+ T cells, and (C) intracellular staining of IFN- were determined 
by FACS, and (D) the secretion of cytokines and proliferation of T cells 
were determined by ELISA and BrdU assay, respectively. The results shown 
are representative of at least four separate experiments and are expressed 
as means ± SEM. Significant differences compared with normal mono-
cytes are indicated (*, P < 0.05; and **, P < 0.01).
Figure 7.  Blockade of PD-L1 improved monocyte-mediated T cell 
activation in vivo. (A) Blocking PD-L1 in TSN-conditioned monocytes 
results in tumor regression in vivo. Mice were injected with human HepG2 
cells, as described in Materials and methods. The control animals () re-
ceived no further injections. The experimental treatments entailed injec-
tions with tumor-specific T cells in combination with untreated monocytes 
() or TSN-exposed monocytes (), or TSN-exposed monocytes pretreated 
with an anti–PD-L1 antibody () or a control antibody (). The illustrated 
data represent means ± SD of tumor volumes (n = 8 tumors in each group 
of four mice). The day of T cell injection was counted as day 0. The results 
shown in A are representative of three separate experiments and are ex-
pressed as means ± SEM. *, P < 0.05 compared with control antibody. CTL, 
tumor-specific T cells; MO, monocytes; TMO, TSN-exposed monocytes.  
(B) The tumors were excised and photographed 21 d after injecting the cells. 
One out of three separate experiments is shown in B.JEM VOL. 206, June 8, 2009 
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and nontumor (at least 3 cm away from the tumor site) tissues from 28 pa-
tients (Group 2) were used for the isolation of peripheral leukocytes, and tu-
mor- and nontumor-infiltrating leukocytes. The clinical characteristics of all 
patients are summarized in Table S3.
Control blood samples were obtained from 28 healthy blood donors at-
tending the Guangzhou Blood Center, all of whom were negative for anti-
bodies against hepatitis C virus, hepatitis B virus, HIV, and syphilis. All 
samples were anonymously coded in accordance with local ethical guidelines 
(as stipulated by the Declaration of Helsinki), and written informed consent 
was obtained and the protocol was approved by the Review Board of Sun 
Yat-Sen University Cancer Center.
Isolation of mononuclear cells from peripheral blood and tissues. 
Peripheral leukocytes were isolated by Ficoll density gradient centrifugation 
(7). Fresh tumor- and nontumor-infiltrating leukocytes were obtained as 
previously described (41). In short, liver biopsy specimens (n = 28) were cut 
into small pieces and digested in RPMI 1640 supplemented with 0.05%   
collagenase IV (Sigma-Aldrich), 0.002% DNase I (Roche), and 20% FCS 
(HyClone Laboratories) at 37°C for 20 min. Dissociated cells were filtered 
through a 150-µm mesh and separated by Ficoll centrifugation. The mono-
nuclear cells were washed and resuspended in medium supplemented with 
1% heat-inactivated FCS for FACS analysis.
ELISPOT assay. Tumor monocytes and T cells were purified from HCC-
infiltrating leukocytes in a MACS column purification system (Miltenyi Bio-
tec). ELISPOT assays were performed using a commercial set (BD) according 
to the manufacturer’s instructions. In brief, 96-well nitrocellulose plates (Mil-
lipore) were coated with 5 µg/ml anti–human IFN- capture antibody at 4°C 
overnight. The wells were then washed and blocked for 2 h at room tempera-
ture with 10% FBS–RPMI 1640 medium. 105 purified tumor T cells were 
left untreated or cultured with autologous tumor monocytes (5:1) in the pres-
ence of 25 µg/ml of tumor mass lysates and incubated for 20 h. After wash, 
the plates were incubated with 2 µg/ml of biotinylated anti–human IFN- 
detection antibody and developed with streptavidin–horseradish peroxidase, 
followed by the addition of 3-amino-9-ethylcarbazole substrate reagent.
Flow cytometry. Peripheral blood leukocytes and tumor- and nontumor-
infiltrating leukocytes were stained with fluorochrome-conjugated mAbs 
against PD-L1, CD14, CD80, CD86, or HLA-DR, or control antibodies 
(BD or eBioscience) according to the manufacturer’s instructions, and they 
were subsequently analyzed by multicolor flow cytometry.
Cell lines and preparation of TSNs. Human hepatoma (SK-Hep-1 and 
HepG2) cell lines were obtained from American Type Culture Collection; 
normal liver (LO2) cells were obtained from the Institute of Biochemistry 
and Cell Biology at the Chinese Academy of Sciences; and the stable hyal-
uronan synthase 2–knockdown SK-Hep-1 clones (SiHAS2) and the mock 
transfectants were established in our previous study (7, 42). All cells were 
tested for mycoplasma contamination using a single-step PCR method (43), 
and they were maintained in DMEM supplemented with 10% FCS. TSNs 
were prepared as previously described (7, 16).
Regulation of PD-L1 expression. Fresh blood monocytes were cul-
tured for the indicated times with TSNs or different concentrations of 
rhIL-10 and rhTNF- (R & D Systems). In some experiments, before ex-
posure to TSNs, the cells were pretreated with neutralizing mAbs against 
20 µg/ml IL-6, 10 µg/ml IL-10, or 1 µg/ml TNF- (R & D Systems), or 
with hyaluronan-blocking peptide (200 µg/ml pep-1; GL Biochem). Cells 
were subject to FACS analysis to detect surface PD-L1 protein, and the 
levels of TNF-, IL-12p70, IL-1, IL-6, and IL-10 in culture supernatants 
were detected by ELISA (eBioscience).
Immunohistochemistry  and  immunofluorescence.  Paraffin-embed-
ded and formalin-fixed samples were cut into 5-µm sections, which were 
then processed for immunohistochemistry as previously described (7). After 
from activated monocytes, stimulated monocyte PD-L1 ex-
pression. Furthermore, in vitro study using recombinant 
TNF- and IL-10 indicated that IL-10 was essential for 
PD-L1 induction and that proinflammatory TNF- acted 
synergistically with antiinflammatory IL-10 to enhance PD-L1 
expression on monocytes. Moreover, comparison of the 
kinetics of cytokine production (7) and PD-L1 expression 
(Fig. 2 A) in TSN-treated monocytes revealed that accumula-
tion of TNF- and IL-10 preceded the up-regulation of PD-L1. 
Such sequential cytokine production and PD-L1 expression 
on TSN-activated monocytes may reflect a novel immune-
editing mechanism by which tumors render activated mono-
cytes to perform a suppressive role by stimulating PD-L1 
expression. This hypothesis is compatible with previous stud-
ies  showing  that  the  proinflammatory  cytokines  IL-1  or 
TNF- can significantly enhance IFN-–dependent indole-
amine 2,3-dioxygenase expression on epithelial cells (35, 36).
In addition to PD-L1, another member of the B7 family, 
B7-H4, is also selectively expressed by various cellular com-
ponents in the tumor microenvironment (4, 28). High levels 
of B7-H4 have been detected on a fraction of tumor-associated 
M in patients with ovarian carcinoma, and these B7-H4+ 
M were found to inhibit tumor-specific T cell effector func-
tion both in vitro and in vivo (37). Moreover, regulatory   
T cells can trigger production of IL-10 by APCs, which in turn 
stimulates such cells to express B7-H4 in an autocrine man-
ner  and  renders  them  immunosuppressive  via  the  B7-H4 
molecules (38). Therefore, manipulating the expression of 
and signaling through these molecules may open new avenues 
for developing novel immune-based therapies to enhance   
antitumor immunity in human cancer (39, 40).
Emerging evidence indicates that it is not inflammation 
per se but inflammatory “context” that determines the ability 
of  proinflammatory  factors  to  facilitate  or  prevent  tumor 
growth. Our results suggest that there is fine-tuned collabor-
ative action between immune activation and immunosup-
pression in tumor microenvironments. Soluble factors derived 
from cancer cells can trigger transient activation of newly re-
cruited monocytes in the peritumoral stroma area, and thereby 
induce the monocytes to produce significant amount of cy-
tokines, including TNF- and IL-10, which in turn leads to 
the expression of PD-L1 (B7-H1) protein on their surface 
and ultimately impairs the antitumor T cell immunity. These 
findings provide important new insight into the significance 
about how activated monocytes in tumors may perform a 
suppressive role by stimulating PD-L1 (B7-H1) expression, 
which would be helpful for the rational design of novel im-
mune-based anticancer therapies.
MATERIALS AND METHODS
Patients and specimens. Tumor or peripheral blood samples were ob-
tained from 312 untreated patients with pathologically confirmed HCC at 
the Sun Yat-Sen University Cancer Center. Of these, 262 patients who un-
derwent curative resection between 1999 and 2004 (designated Group 1) 
had complete follow-up data, and they were further enrolled for analysis of 
OS and DFS. Clinical stages were classified according to the International 
Union against Cancer. Blood samples from 28 patients as well as fresh tumor 1336 MONOCYTE ACTIVATION AND IMMUNE EVASION | Kuang et al.
Online supplemental material. Fig. S1 shows the regulation of T cell cy-
totoxicity by TSN-exposed PD-L1+ monocytes. Table S1 summarizes the 
blocking effects of IL-10, TNF-, and IL-6 in the co-culture system by use 
of specific mAbs. Table S2 shows the association of peritumoral stroma 
CD68 cells with clinicopathological characteristics. Table S3 lists the clinical 
characteristics of 312 patients with HCC. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20082173/DC1.
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